UnitedHealth Group Incorporated UNH SPXR3KPHARMA
Company Overview
UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. It operates through four segments: Optum Health, Optum Insight, Optum Rx; and UnitedHealthcare. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services with patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, public entities, life sciences companies and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease and drug therapy management. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; Medicaid plans, including Temporary Assistance to Needy Families; Children's Health Insurance Programs; Dual SNPs; Long-Term Services and Supports; Aged, Blind and Disabled; and other federal, state, and community health care programs. and health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. UnitedHealth Group Incorporated was founded in 1974 and is based in Eden Prairie, Minnesota.
Why Investors Should Care
Revenue has grown at a 10.4% CAGR over the past five years.
Offers a dividend yield of 2.33%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $447.57B (+11.8% YoY); net profit $12.06B.
- Trailing 12 Months Year-on-year growth — revenue +0.4%, earnings +61.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.4%, profit CAGR 5.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.40% |
| 1 Year: | 0.40% |
Compounded Profit Growth
| 5 Years: | 5.43% |
| 1 Year: | 61.50% |
Stock Price Performance
| 1 Year: | +50.02% |
| 6 Months: | +40.50% |
| 3 Months: | -0.02% |
| 1 Month: | -1.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)46.82 · Neutral
P/E of 25.54 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 7 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 8 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 608.52 | 32.79 | $225.00B | 0.32% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.41B | 30.62B | 31.12B | 31.71B | 32.57B | 32.76B | 35.76B | 36.26B | 41.49B | 44.53B | 46.48B | 46.29B | 48.72B | 50.05B | 50.32B | 55.19B | 56.09B | 56.56B | 60.31B | 60.59B | 60.35B | 64.42B | 62.14B | 65.11B | 70.20B | 71.32B | 72.34B | 80.15B | 80.33B | 80.89B | 91.93B | 92.90B | 92.36B | 99.80B | 98.86B | 100.82B | 109.58B | 111.62B | 113.16B | 111.72B |
| Operating Income | 2.40B | 2.63B | 2.45B | 2.05B | 2.55B | 2.90B | 2.64B | 2.90B | 3.02B | 2.96B | 3.20B | 3.58B | 3.41B | 3.73B | 4.09B | 4.05B | 4.20B | 4.59B | 4.83B | 4.74B | 5.01B | 5.00B | 9.24B | 4.65B | 6.74B | 5.98B | 5.71B | 6.95B | 7.13B | 7.46B | 8.09B | 8.06B | 8.53B | 7.93B | 7.88B | 8.71B | 9.12B | 5.15B | 4.32B | 8.99B |
| Net Income | 1.44B | 1.57B | 1.43B | 1.10B | 1.41B | 1.60B | 1.41B | 1.58B | 1.60B | 1.61B | 1.75B | 1.97B | 2.17B | 2.28B | 2.48B | 2.84B | 2.92B | 3.19B | 3.47B | 3.29B | 3.54B | 3.38B | 6.64B | 3.17B | 4.86B | 4.27B | 4.09B | 5.03B | 5.07B | 5.26B | 5.61B | 5.47B | 5.84B | -1.41B | 4.22B | 6.05B | 6.29B | 3.41B | 2.35B | 6.28B |
| Diluted EPS | 1.40 | 1.53 | 1.41 | 1.10 | 1.42 | 1.63 | 1.46 | 1.64 | 1.65 | 1.67 | 1.81 | 2.03 | 2.23 | 2.32 | 2.51 | 2.87 | 2.98 | 3.24 | 3.56 | 3.42 | 3.67 | 3.52 | 6.91 | 3.30 | 5.08 | 4.46 | 4.28 | 5.27 | 5.34 | 5.55 | 5.95 | 5.82 | 6.24 | -1.53 | 4.54 | 6.51 | 6.85 | 3.74 | 2.59 | 6.90 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75.43B | 81.19B | 87.14B | 94.16B | 101.86B | 110.62B | 122.49B | 130.47B | 157.11B | 184.84B | 201.16B | 226.25B | 242.16B | 257.14B | 287.60B | 324.16B | 371.62B | 400.28B | 447.57B |
| Operating Income | 7.85B | 5.26B | 6.36B | 7.86B | 8.46B | 9.25B | 9.62B | 10.27B | 11.02B | 12.93B | 15.21B | 17.34B | 19.68B | 22.41B | 23.97B | 28.43B | 32.36B | 32.29B | 18.96B |
| Net Income | 4.65B | 2.98B | 3.82B | 4.63B | 5.14B | 5.53B | 5.62B | 5.62B | 5.81B | 7.02B | 10.56B | 11.99B | 13.84B | 15.40B | 17.29B | 20.12B | 22.38B | 14.40B | 12.06B |
| Diluted EPS | 3.42 | 2.40 | 3.24 | 4.10 | 4.73 | 5.28 | 5.50 | 5.70 | 6.01 | 7.25 | 10.72 | 12.19 | 14.33 | 16.03 | 18.08 | 21.18 | 23.86 | 15.51 | 13.23 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 55.81B | 59.05B | 63.06B | 67.89B | 80.89B | 81.88B | 86.30B | 111.25B | 122.81B | 139.06B | 152.22B | 173.89B | 197.29B | 212.21B | 245.71B | 273.72B | 298.28B | 309.58B |
| Total Equity | 20.81B | 20.06B | 20.78B | 23.61B | 25.82B | 28.29B | 31.18B | 32.15B | 32.45B | 33.73B | 38.18B | 49.83B | 54.32B | 60.44B | 68.33B | 75.05B | 81.45B | 94.42B | 98.27B | 100.09B |
| Cash & Equivalents | 10.32B | 8.87B | 7.43B | 9.80B | 9.12B | 9.43B | 8.41B | 7.28B | 7.50B | 10.92B | 10.43B | 11.98B | 10.87B | 10.98B | 16.92B | 21.38B | 23.36B | 25.43B | 25.31B | 24.36B |
| Long Term Debt | - | - | 11.34B | 9.01B | 8.66B | 10.66B | 14.04B | 14.89B | 16.01B | 25.33B | 25.78B | 28.84B | 34.58B | 36.81B | 38.65B | 42.38B | 54.51B | 58.26B | 72.36B | 72.32B |
| Total Liabilities | - | - | 35.03B | 35.44B | 37.24B | 39.60B | 47.59B | 48.56B | 52.54B | 75.79B | 82.62B | 87.04B | 95.99B | 111.73B | 126.75B | 135.73B | 159.36B | 174.80B | 195.69B | 207.88B |
| Current Liabilities | - | - | 19.76B | 22.16B | 23.70B | 23.92B | 27.12B | 27.88B | 30.62B | 42.90B | 49.25B | 50.46B | 53.21B | 61.78B | 72.42B | 78.29B | 89.24B | 99.05B | 103.77B | 114.90B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.88B | 4.24B | 5.62B | 6.27B | 6.97B | 7.16B | 6.99B | 8.05B | 9.74B | 9.79B | 13.60B | 15.71B | 18.46B | 22.17B | 22.34B | 26.21B | 29.07B | 24.20B | 19.70B |
| Investing Cash Flow | -4.15B | -5.07B | -976.00M | -5.34B | -4.17B | -8.65B | -3.09B | -2.53B | -18.39B | -9.36B | -8.60B | -12.38B | -12.70B | -12.53B | -10.37B | -28.48B | -15.57B | -20.53B | -8.69B |
| Financing Cash Flow | -3.19B | -605.00M | -2.27B | -1.61B | -2.49B | 471.00M | -4.95B | -5.29B | 12.24B | -1.01B | -3.44B | -4.37B | -5.62B | -3.59B | -7.46B | 4.23B | -11.53B | -3.51B | -11.64B |
| Capital Expenditure | -871.00M | -791.00M | -739.00M | -878.00M | -1.07B | -1.07B | -1.31B | -1.52B | -1.56B | -1.71B | -2.02B | -2.06B | -2.07B | -2.05B | -2.45B | -2.80B | -3.39B | -3.50B | -3.62B |
| Free Cash Flow | 5.01B | 3.45B | 4.89B | 5.39B | 5.90B | 6.08B | 5.68B | 6.53B | 8.18B | 8.09B | 11.57B | 13.65B | 16.39B | 20.12B | 19.89B | 23.40B | 25.68B | 20.70B | 16.07B |
| Share Buybacks | 6.60B | 2.68B | 1.80B | 2.52B | 2.99B | 3.08B | 3.17B | 4.01B | 1.20B | 1.28B | 1.50B | 4.50B | 5.50B | 4.25B | 5.00B | 7.00B | 8.00B | 9.00B | 5.54B |
| Dividends Paid | 40.00M | 37.00M | 36.00M | 449.00M | 651.00M | 820.00M | 1.06B | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 10.4% | 6.5% | 7.3% | 8.4% | 8.3% | 8.4% | 7.9% | 7.9% | 7.0% | 7.0% | 7.6% | 7.7% | 8.1% | 8.7% | 8.3% | 8.8% | 8.7% | 8.1% | 4.2% |
| Net Margin % | 6.2% | 3.7% | 4.4% | 4.9% | 5.0% | 5.0% | 4.6% | 4.3% | 3.7% | 3.8% | 5.2% | 5.3% | 5.7% | 6.0% | 6.0% | 6.2% | 6.0% | 3.6% | 2.7% |
| ROE % | 23.2% | 14.3% | 16.2% | 17.9% | 18.2% | 17.7% | 17.5% | 17.3% | 17.2% | 18.4% | 21.2% | 22.1% | 22.9% | 22.5% | 23.0% | 24.7% | 23.7% | 14.7% | 12.0% |
| ROCE % | - | 14.6% | 17.2% | 20.0% | 19.3% | 17.2% | 17.8% | 18.5% | 16.1% | 17.6% | 17.2% | 17.5% | 17.6% | 17.9% | 17.9% | 18.2% | 18.5% | 16.6% | 9.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.56% | 76.86M | $30.20B |
| 2 | Vanguard Capital Management LLC | 6.61% | 59.31M | $23.31B |
| 3 | State Street Corporation | 5.08% | 45.63M | $17.93B |
| 4 | Capital World Investors | 3.33% | 29.89M | $11.74B |
| 5 | FMR, LLC | 3.12% | 27.99M | $11.00B |
| 6 | Vanguard Portfolio Management LLC | 2.73% | 24.48M | $9.62B |
| 7 | Price (T.Rowe) Associates Inc | 2.58% | 23.15M | $9.10B |
| 8 | Geode Capital Management, LLC | 2.42% | 21.75M | $8.55B |
| 9 | JPMORGAN CHASE & CO | 2.26% | 20.25M | $7.96B |
| 10 | Charles Schwab Investment Management, Inc. | 2.21% | 19.83M | $7.79B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UNH
Is UNH Stock Set For Another 12% Rally? Analyst Says Medical Cost Trends, Supportive Data Points Leading Toward Favorable Q2 - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPMXVtYmFPeUQ2cWkta1JBbzJnNGtGZ2ZRSFU0VTRwaUVuZ0NVblJHdGcyblQ2Um9GUzlYQW54UUhyQW1YQ2RISTBaQU91U1NVbVE0RHJfOVpFQlAtN2VSc3otbG5fOEJFX3RSTmNaNDFCUWJxVXpUZHZ1MVpZLUJIUzB5YUN5aWRscjI4OV…
UnitedHealth Beats Q1 2026 and Raises Guidance - Is UNH Stock a Buy After Jumping 8%? - tradingkey.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNeVh0WFN6TXVzUmhmdTNvWGdpOXJxdmFLUml1V09vZi1zSHZTMDduOUhZUXdWc2h1d3U5QnJUZDl4aHJqZXplcndqZnlIYmlvb0x0eVdSaHFEN1FrcENkV0s3N3BYM0g2NndDUmtJeVZnZnlOcDh6NXJXLVB0ZE1UVjZYLXBXRUt1WXAxQ1…
$100 Invested In UnitedHealth Group 20 Years Ago Would Be Worth This Much Today - Benzinga
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQXzVYLXl1ZmpONjVqMWtZTW45UmstNEVoSHZlWENiUUpWdWloSk1jQzJneUVDakdqN19GbFdKdmFIaVozQVlxNHc1NU9xLUJ0cWUtVEs0bXFDT2x3ZWczTjk2STBWLUFoVVktSU5tRkI1RTNiUjYxXzM1X3pGcWxkSEo3cGpYaVlKU1hyV3…
UnitedHealth (UNH) Stock May Look Reasonable Despite IRS Tax Scrutiny - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNSTZxel9QbkEtREV3T3JzNUdCaXFTLVpRaFVvQnZsTjhobzc1b3Y2QXMtaHFkaUd3ZHdpUWFtT2M1MENpTVM1cFlkQ2RhOFQ5UVY1X21kd3UxaThTM2lPSWozRGFjRHI5T2doWHAweWlRNzVLcjY3UjI1MDIyUzNGakY2T2tfM1ZjdGRFZW…
UnitedHealth Stock Is Up 39% in Six Months. - TIKR.com
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFBJbktEMFZGWFZIN2ZJd2tJdHRMbFFuMXE5Y2d5MmNpdnN0enpfRGloaDdVWmVGazR4WG9SeXZNa1NBeTZKaHFvWmRCdjVSUUZTaUlaLTNMUkdlNndzbnpwNVJzTkxtcjV4UzE3eXRJSDlDdlV4U1E?oc=5" target="_blank">UnitedHe…
UNH Stock Becomes Dow’s Biggest Driver Back To 50,000 — Will Trump Tailwinds Spark Another Leg Higher? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPc09TZEpPUXhaQndxcjc0MUd3T1RhaTNMb2FIamg3MWlfNWR0VHc5QXk0S01oQk9ucTBrcmRMRFdhOUd0MDE5NlBUWnBvOExFeVdyTHdyaDdIanE1YlRCd0VUbk5RZXNJSW9yVmRHejRVR0duRHJJS0U2dThGSmlHTzVmYzFEdzZfZER1aC…
UNH — Frequently Asked Questions
What is the current share price of UnitedHealth Group Incorporated (UNH)?
As of 2026-09-07 16:24 PDT, UnitedHealth Group Incorporated (UNH) trades at $397.14 on NYSE. Its 52-week range is $257.55 to $436.35.
What is the market capitalisation of UNH?
UnitedHealth Group Incorporated (UNH) has a market capitalisation of $356.47B on NYSE.
What is the P/E ratio of UNH?
UNH trades at a trailing price-to-earnings (P/E) ratio of 25.54. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.48.
Does UNH pay a dividend?
UnitedHealth Group Incorporated (UNH) currently offers a dividend yield of 2.33%.
What is the return on equity (ROE) of UNH?
UNH has a return on equity (ROE) of 14.15%. Its return on capital employed (ROCE) is 9.74%.
Is UNH a good stock to buy?
This page provides a data-driven analysis of UnitedHealth Group Incorporated (UNH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.